THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 1 RESULTS

In Segment C, participants will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment till disease progression or perhaps the contributors are not able to tolerate the study drugs.- "Our study disclosed the crucial role of the KLF16/MYC regulatory axis in modulating tu